BCL9 is associated with B-cell acute lymphoblastic leukemia. It may be a target of translocation in B-cell malignancies with abnormalities of 1q21. Its function is unknown. The overexpression of BCL9 may be of pathogenic significance in B-cell malignancies. [provided by RefSeq, Jul 2008].
Miller, Rutherford, Johnson, Fiedler, Bienz: "Allosteric remodelling of the histone H3 binding pocket in the Pygo2 PHD finger triggered by its binding to the B9L/BCL9 co-factor." in: Journal of molecular biology, Vol. 401, Issue 5, pp. 969-84, (2010) (PubMed).
Fritzmann, Morkel, Besser, Budczies, Kosel, Brembeck, Stein, Fichtner, Schlag, Birchmeier: "A colorectal cancer expression profile that includes transforming growth factor beta inhibitor BAMBI predicts metastatic potential." in: Gastroenterology, Vol. 137, Issue 1, pp. 165-75, (2009) (PubMed).
Sampietro, Dahlberg, Cho, Hinds, Kimelman, Xu: "Crystal structure of a beta-catenin/BCL9/Tcf4 complex." in: Molecular cell, Vol. 24, Issue 2, pp. 293-300, (2006) (PubMed).
Brembeck, Schwarz-Romond, Bakkers, Wilhelm, Hammerschmidt, Birchmeier: "Essential role of BCL9-2 in the switch between beta-catenin's adhesive and transcriptional functions." in: Genes & development, Vol. 18, Issue 18, pp. 2225-30, (2004) (PubMed).